Clinical research in febrile neutropenia in cancer patients: Past achievements and perspectives for the future

doi:10.5495/wjcid.v6.i3.37

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (15358)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-8) series.

Item

Count

PDF

877

WORD

473

HTML

10283

Figures (1-4)

519

Tables (1-8)

300

Sum=12452

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1290

Download

1616

Sum=2906

Aug 25, 2016 (publication date) through Dec 2, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Clinical Infectious Diseases

ISSN

2220-3176

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Infect Dis. Aug 25, 2016; 6(3): 37-60
Published online Aug 25, 2016. doi: 10.5495/wjcid.v6.i3.37

Table 7 Possible causes of fever in high risk neutropenic patients unresponsive to broad spectrum antimicrobials[139]

Infectious causes	Frequency
Fungal infections responding (40%)/resistant (5%) to empiric ATB	45%
Bacterial Infections (cryptic foci, biofilm, resistant organism)	10%
Toxoplasma gondii, mycobacteria, legionella, mycoplasma, chl.pneumoniae	5%
Viral infections (HSV, CMV, EBV, HHV6, VZ, parainfluenza, RSV, influenza)	5%
Graft vs host disease in hematopoietic stem cell transplantation	10%
Undefined (drug, toxic effects of chemotherapy, antitumor response, undefined pathogens)	25%

HSV: Herpes simplex virus; CMV: Cytomegalovirus; EBV: Epstein-Barr virus; HHV6: Human herpesvirus 6; RSV: Respiratory syncytial virus.

Citation: Klastersky J, Paesmans M, Aoun M, Georgala A, Loizidou A, Lalami Y, Dal Lago L. Clinical research in febrile neutropenia in cancer patients: Past achievements and perspectives for the future. World J Clin Infect Dis 2016; 6(3): 37-60
URL: https://www.wjgnet.com/2220-3176/full/v6/i3/37.htm
DOI: https://dx.doi.org/10.5495/wjcid.v6.i3.37